Edition:
United Kingdom

Fortis Healthcare Ltd (FOHE.NS)

FOHE.NS on National Stock Exchange of India

141.45INR
14 Dec 2018
Change (% chg)

Rs-10.15 (-6.70%)
Prev Close
Rs151.60
Open
Rs151.70
Day's High
Rs152.00
Day's Low
Rs130.00
Volume
19,939,263
Avg. Vol
1,896,402
52-wk High
Rs171.25
52-wk Low
Rs107.10

Summary

Name Age Since Current Position

Ravi Rajagopal

63 2018 Chairman of the Board

Girish Gupta

2018 Interim Chief Financial Officer

Sumit Goel

2018 Interim Company Secretary

Bhagat Chintamani Aniruddha

48 2018 Additional Director

Boon Kheng Chan

49 2018 Additional Director

Soon Teck Low

53 2018 Additional Director

See Leng Tan

53 2018 Additional Director

Sunil Godhwani

2009 Non-Executive Non-Independent Director

Indrajit Banerjee

62 2018 Independent Director

Suvalaxmi Chakraborty

52 2018 Independent Director

Gurcharan Das

71 2000 Non-Executive Independent Director

Joji Gill

2012 Non-Executive Independent Director

Shradha Marwah

2015 Additional Non-Executive Independent Director

Anurag Kalra

IR Contact Officer

Biographies

Name Description

Ravi Rajagopal

Mr. Ravi Rajagopal serves as Chairman of the Board of the Company. He was Independent Director of the Company. He is a Chartered Accountant and has a 35 year career in major consumer goods businesses. He has held several positions at ITC from 1979 to 1995, where he was involved in Packaging, Tobacco Farming, Agri-Businesses, Financial Services and Tobacco Marketing. He was head of Finance and Commercial at Ranbaxy Laboratories from 1995 to 1996, after which he moved to Diageo pie, where he held several positions including Finance Director for India and South Asia, Chief Financial Officer for Venture Markets and International Region, Group Financial Controller, Managing Director for India and South Asia and Chief Financial Officer for Europe. From 2010 to 2015, he was Global Head for Mergers and Acquisitions at Diageo Plc. Where he held several positions including Finance Director for India and South Asia, Chief Financial Officer for Ventures Markets and International Region, Group Financial Controller, Managing Director for India and South Asia and Chief Financial Officer for Europe. From 2010 to 2015, He was Global Head for Mergers and Acquisitions at Diageo Plc. He currently serves as Chairman for JM Financial Services Singapore, as well as an Independent Director and Chairman of the Audit Committee for Vedanta Resources Plc. He is a Senior Advisor to Joseph Hage Aaronson, a London-based litigation and arbitration law firm and Advisor to Good Relations India, which advises UK businesses on market entry and positioning strategies in India. He is an Association Member of BUPA. Earlier board experience includes serving as Non-Executive Director in United Spirits from 2013 to 2016, as well as forming and leading Diageo's India Advisory Board on India Strategy and Business Development between 2008 and 2015.

Girish Gupta

Mr. Girish Gupta is Interim Chief Financial Officer of the Company. He is a Commerce Graduate from Shriram College of Commerce and a qualified Chartered Accountant from The Institute of Chartered Accountants of India. He is a global finance executive with 38 years of post-qualification experience across organizations and prior to joining Fortis, was working as an Advisor, on operations of Insolvency and bankruptcy assignment for a public listed Company and special assignments for NCLT.

Sumit Goel

Mr. Sumit Goel is Interim Company Secretary of the Company. Mr. Goel is Fellow Member of the Institute of Company Secretaries of India and a Commerce and Law Graduate from Delhi University. He has comprehensive and extensive experience of 16 years in secretarial and compliance management in various organizations.

Bhagat Chintamani Aniruddha

Mr. Bhagat Chintamani Aniruddha is Additional Director of the Company. He is currently the overseeing Executive Director for the Healthcare sector of the Investments Division of Khazanah Nasional Berhad ("Khazanah") and concurrently leads Khazanah's India operations. He also serves on certain Boards and Board Committees of IHH subsidiaries under Acibadem Saglik Yatirimlari Holding A.S. Group. Prior to joining Khazanah, Mr Bhagat spent 14 years at McKinsey & Company in Singapore, including six years as Managing Partner for the Singapore office. He was a leader in the healthcare practice, serving hospital systems across Asia; as well as a leader in the Principal Investor practice, serving several sovereign wealth funds, private equity firms, and family owned businesses. He also founded and led McKinsey's corporate governance service line. Preceding his time in McKinsey, Mr Bhagat held various positions at an engineering and construction firm in India, which culminated in his role as the Chief Executive Officer for the firm. He is also a qualified architect. Further, Mr. Bhagat Chintamani Aniruddha declared that, he is not debarred from accessing the capital markets and / or restrained from holding any position / office of director in a company pursuant to order of SEBI or any other such authority.

Boon Kheng Chan

Dr. Chan Boon Kheng is Additional Director of the Company. Dr Chan Boon Kheng has more than 20 years of experience as a healthcare executive working in several geographies including South East Asian countries and the Middle East. He has held senior executive positions in the healthcare service industry covering a span of roles which includes operation, corporate and investment portfolios. He has a track record in growing new businesses, developing strong teams and delivering results. He has a long association with IHH and its predecessor entity Parkway Healthcare from 2000-2010. Among the various positions he held, he was the Group Chief Executive Officer of Pantai Holdings Berhad (“Pantai”). Pantai is one of the largest hospital group in Malaysia with a chain of 12 hospitals from 2007-2010. He returned to IHH in 2018 to lead the IHH Strategic Planning and Business Development (Merger & Acquisition) and is CEO for its South East Asia Operations. Prior to joining IHH in 2018, he was a senior advisor to TPG, a global private equity fund. From 2010-2016, he was the Group President of Sasteria Pte Ltd, a privately held healthcare entity, which owns Thomson Medical Group based in Singapore and TMC Life Sciences based in Kuala Lumpur Malaysia. He concurrently served as the Group CEO of Thomson as well as the Executive Director of TMC Life Sciences Limited. TMC Life Sciences owns and operates a tertiary hospital in Kuala Lumpur and the largest network of fertility centres in Malaysia.

Soon Teck Low

Mr. Low Soon Teck is Additional Director of the Company. He assumed the position of Group Chief Financial Officer of IHH Healthcare Berhad ("IHH") on 10 January 2016. He brings with him over 20 years of experience in finance, legal and general management in leadership roles. Prior to joining IHH, Mr Low served with the RCMA Group, a commodities supply chain management company, as its Chief Financial Officer between 2013 and 2015. From 1994 to 2013, he was employed in the Kuok/Kerry Group, holding various senior positions in diverse businesses within the group in Hong Kong and Singapore. His last position in the group was as Chief Financial Officer of PACC Offshore Services Holdings Group, the offshore marine arm of the Kuok/Kerry Group. Prior to this, Mr Low served as Group Treasurer at Wilmar International Limited, after its merger in 2006 with Kuok Oils and Grains where he had served as Group Financial Controller following his relocation from Hong Kong to Singapore in 2005.

See Leng Tan

Dr. Tan See Leng is Additional Director of the Company. Dr Tan See Leng was appointed the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") in January 2014 after serving as an Executive Director on the IHH Board for two years. Dr Tan is also the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, IMU Health Sdn Bhd and Acibadem Saglik Yatirimlari Holding A.S. (“ASYH”) Group and a Board Committee of ASYH. Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to one of the leading global health-plan providers. With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees such as Singapore Ministry of Health's MediShield Life Review Committee. He has been reappointed Adjunct Assistant Professor of DukeNUS Graduate Medical School Singapore, Office of Education, for the period until 2019. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust which is listed on the Singapore Exchange Securities Trading Limited.

Sunil Godhwani

Mr. Sunil Godhwani is Non-Executive Non-Independent Director of the Company. He is a graduate in Chemical Engineering and has a Master’s Degree in Industrial Engineering & Finance from Polytechnic Institute of New York. He has 20 years of experience in business. He is the CEO & Managing Director of Religare Enterprises Limited and the Chairman and Managing Director of Religare Securities Limited.

Indrajit Banerjee

Mr. Indrajit Banerjee serves as Independent Director of the Company. He is a Chartered Accountant and has a corporate career spanning over 35 years. Over the last 20 years he has played a key role in senior leadership positions, principally in Ranbaxy, Cairn India, Lupin and Indal, dealing with unique business criticalities which led to the organisations realising their potential values. Between 1982 and 1999 he was at Indal, of which the final two years he was Chief Financial Officer, where he played a key role in the strategy formation and risk management in the company during the transformation stage. He joined Lupin ltd in 2002, where he addressed the critical liquidity challenges faced by the company and led the entry of a set of private equity investors that helped re-brand the company. In 2005, he joined Cairn India ltd, where he guided the financing of the country's largest greenfield upstream onshore oil and gas development project which was the first large project of its size and complexity in India. He was also President and CFO, and a Member of the Executive Committee, at Ranbaxy Laboratories Ltd between 2011 and 2015, where he helped the company sustain itself through its most challenging times and played a critical role in the process leading to the merger of the company with Sun Pharma, later leading the integration of businesses and processes of the merged entity post-merger. Since November 2015 he has engaged in certain specific management consultancy services, including business structuring and planning; management of growth situations; management of crisis situations through cash flow monitoring, prioritisation of operational requirements and bank relationship management; financing of working capital and establishment of Risk Management processes in multi-business and multi-regional organisations; business and financial process integration for existing organisations as well as for merging entities.

Suvalaxmi Chakraborty

Ms. Suvalaxmi Chakraborty serves as Independent Director of the Company. She is a Chartered Accountant and has 28 years of experience in the field of financial services and banking. She has featured in the Fortune India List of 50 most powerful women in business. She held several positions at ICICI Ltd and ICICI Bank between 1989 and 2006, including General Manager for Corporate Banking and Head of Rural, Micro-banking and Agri Business. She was Director on the Board of Fixed Income Money Markets and Derivatives Association (FIMMDA) for over 2 years and headed the working committee (New Products) in FIMMDA (representing ICICI). She launched and ran the commercial banking business of Barclays Bank in India from 2007 to 2010, after which she was Chief Executive Office for the Indian operations of State Bank of Mauritius from 2010 to 2013. In 2014, she was also Advisor for Transwarranty Finance Ltd and Positron Consulting Services, with advisory assignments spanning debt syndication, Mergers & Acquisitions and capital raising for midmarket corporates, among others. Currently she serves as an Independent Director for Magma HDI General Insurance Company Ltd, and Caspian Impact Investments Pvt Ltd. She is also serving on the board of RGVN (North East) Microfinance Ltd as a nominee director. She is Co-Founder and Director of Espandere Advisors Private Ltd, which is a Business Advisory and Transaction Advisory services provider in the Banking & Finance, Agriculture & Rural, Infrastructure and Manufacturing sectors. She is also Advisor for Fullerton India Credit Company Ltd, which is a 100% step down subsidiary of Temasek Holdings (Pte) Ltd, Singapore.

Gurcharan Das

Mr. Gurcharan C. Das is Non-Executive Independent Director of the Company. He has graduated with a Bachelor of Arts (Honors) degree cum laude in Philosophy and Government from Harvard University, U.S.A. and holds an MBA degree from Harvard Business School, Harvard University, U.S.A. Mr. Das is an author and a management consultant and advises a number of companies on global corporate strategy. He held the position of the Chief Executive Officer, Procter and Gamble India from 1985 until 1992, and Chairman and Managing Director of Richardson Hindustan Limited from 1981 until 1985. He has over 30 years of experience working in six countries. He is an operating advisor and investor in Chrys Capital LLC. He served on juries of the McKinsey award for Harvard Business Review article for 2005 and the $500,000 Milton Friedman Prize. Mr. Das has served on several Government Boards, including the Foreign Investment Promotion Council in India. He is the author of the book “India Unbound”. He is a regular columnist for the newspapers ‘Times of India’ and the ‘Dainik Bhaskar’ and he contributes occasional articles to the Wall Street Journal and other newspapers.

Joji Gill

Ms. Joji Sekhon Gill is Non-Executive Independent Director of the Copmpany.

Shradha Marwah

Anurag Kalra